schreef:
2. Data, Safety, and Convenience Should Do All the Talking While the Bigger Guys Duke it
Out
While there are established players (Shire, CSL Behring) with large marketing efforts competing with each
other, we believe that once Ruconest hits its stride, meaningful traction can be attained. This commercial
success should be supported by the drug’s differentiated properties for both efficacy and safety, which we
highlight below. Further important support should also come from patient and physician experience with
the drug, especially from a safety standpoint, and not having to rely upon the blood supply for protein
isolation, and associated potential risks